Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mezlocillin + netilmicin is a fixed-dose combination of two antibiotics used primarily for the prophylaxis and treatment of serious bacterial infections, especially in surgical settings such as cardiac pacemaker implantation[1][2]. Mezlocillin is an extended-spectrum penicillin (beta-lactam antibiotic) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis[3][8][10]. Netilmicin is an aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of bacteria, interfering with protein synthesis by causing misreading of mRNA and production of nonfunctional or toxic peptides[4][6]. The combination provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. This synergistic effect makes it particularly useful for preventing infections caused by methicillin-resistant staphylococci and other difficult-to-treat organisms in high-risk surgical procedures[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mezlocillin + netilmicin.